Skip to content

Christian Schulz-Quach

3 papers in the library · 100 citations · publishing 2024-2026

Papers

Sort Most recent Most cited

Intranasal Ketamine for Existential Distress in Advanced Cancer.

Journal of Pain and Symptom Management August 1, 2026 Stefan Aguiar, Mary Makarious, Orly Lipsitz et al.

Depression and existential distress are highly prevalent among patients with advanced cancer, and there is growing evidence for ketamine as a rapidly acting antidepressant in the population, but few studies have examined existential distress outcomes with ketamine treatment. The INKeD-PC trial demonstrated efficacy of intranasal racemic ketamine for depression in patients with cancer receiving...

Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression

Journal of Psychopharmacology July 1, 2025 Ryan M Brudner, Erica Kaczmarek, Marc G Blainey et al. 3 citations

Background: Psilocybin-assisted psychotherapy (PAP) is a promising treatment for various psychiatric disorders. However, the exact biological and psychological mechanisms of action of PAP remain to be determined. Examining predictors of PAP outcomes may help identify necessary processes for positive treatment outcomes. Mystical experiences are considered a key aspect of the subjective effects...

Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.

Med (New York, N.Y.) March 8, 2024 Joshua D. Rosenblat, Shakila Meshkat, Zoe Doyle et al. 97 citations

Psilocybin-assisted psychotherapy (PAP) has been associated with antidepressant effects. Trials to date have typically excluded participants with complex presentations. Our aim was to determine the feasibility of PAP in a complex population, including high levels of treatment resistance in major depressive and bipolar disorder and patients with baseline suicidality and significant comorbidity....